Evidence map›Paper›PMID 34569101›Full record

ArticleClinical transplantation2022

SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications.

Gianluca Russo, Quirino Lai, Luca Poli, Maria Paola Perrone, Aurelia Gaeta, Massimo Rossi, Claudio M Mastroianni, Manuela Garofalo, Renzo Pretagostini

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Pooled it
  2. Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gianluca RussoInfectious Disease Unit, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-8764-7389
Quirino LaiGeneral Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1487-3235
Luca PoliGeneral Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy.
Maria Paola PerroneImmunohematology and Transfusion Medicine Unit, Sapienza University of Rome, Rome, Italy.
Aurelia GaetaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Massimo RossiGeneral Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy.
Claudio M MastroianniInfectious Disease Unit, Sapienza University of Rome, Rome, Italy.
Manuela GarofaloGeneral Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy.
Renzo PretagostiniGeneral Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid organ transplant patients are at a higher risk for poor CoronaVirus Disease-2019 (COVID-19)-related outcomes and have been included as a priority group in the vaccination strategy worldwide. We assessed the safety and efficacy of a two-dose vaccination cycle with mRNA-based COVID-19 vaccine (BNT162b2) among 82 kidney transplant outpatients followed in our center in Rome, Italy. After a median of 43 post-vaccine days, a SARS-CoV-2 anti-Spike seroprevalence of 52.4% (n = 43/82) was observed. No impact of the vaccination on antibody-mediated rejection or graft function was observed, and no significant safety concerns were reported. Moreover, no de novo HLA-donor-specific antibodies (DSA) were detected during the follow-up period. Only one patient with pre-vaccination HLA-DSA did not experience an increased intensity of the existing HLA-DSA. During the follow-up, only one infection (mild COVID-19) was observed in a patient after receiving the first vaccine dose. According to the multivariable logistic regression analysis, lack of seroconversion after two-dose vaccination independently associated with patient age ≥60 years (OR = 4.50; P = .02) and use of anti-metabolite as an immunosuppressant drug (OR = 5.26; P = .004). Among younger patients not taking anti-metabolites, the seroconversion rate was high (92.9%). Further larger studies are needed to assess the best COVID-19 vaccination strategy in transplanted patients.

Indexed as

COVID-19Kidney TransplantationAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesHumansMiddle AgedRisk FactorsSARS-CoV-2Seroepidemiologic StudiesVaccinationAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesBNT162b2 vaccineCOVID-19graft rejectionHLA-DSAkidney transplantationsolid organ transplant patients

Identifiers

PMID34569101
PMCPMC8646240
OpenAlexW3201893920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.